Angiogenesis, Exudation and Degeneration Meeting

MIAMI — A protein that targets tissue factor in neovascular age-related macular degeneration was well tolerated in a phase 1 study, a speaker told colleagues here.

MIAMI — Persistent retinal fluid in eyes that have been treated with anti-VEGFs for neovascular age-related macular degeneration may have a genetic basis, a speaker told colleagues here.

MIAMI — An anti-complement C5 therapy had no different effect on geographic atrophy lesion size than sham therapy, according to a presentation at Angiogenesis, Exudation, and Degeneration 2016.

MIAMI — The frequency of risk alleles predisposing to neovascularization in age-related macular degeneration also predicts neovascularization in pachychoroid disease, according to a study presented here.

MIAMI — Results of the MAHALO study support the use of reading speed as a secondary outcome measure in clinical trials for lampalizumab, a speaker told colleagues here.

MIAMI — Anti-VEGF injections in combination with targeted retinal photocoagulation did not show a decrease in treatment burden in patients with diabetic macular edema in the DAVE trial, according to a presenter here.

MIAMI — Robust investment by venture capitalists is making up for stagnant government funding for medical research, particularly in the ophthalmic and biotechnology sectors, a speaker told colleagues here.

MIAMI — Harry W. Flynn Jr., MD, discussed the newly published and continuing trials of the Diabetic Retinopathy Clinical Research Network at Angiogenesis, Exudation, and Degeneration 2016.